These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 30461207)

  • 101. Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction.
    Valdez IH; Wolff A; Atkinson JC; Macynski AA; Fox PC
    Cancer; 1993 Mar; 71(5):1848-51. PubMed ID: 8448748
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Clinical trial of endorectal amifostine for radioprotection in patients with prostate cancer: rationale and early results.
    Ménard C; Camphausen K; Muanza T; Sears-Crouse N; Smith S; Ben-Josef E; Coleman CN
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):63-7. PubMed ID: 14727242
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Weekly Adaptive Radiotherapy vs Standard Intensity-Modulated Radiotherapy for Improving Salivary Function in Patients With Head and Neck Cancer: A Phase 3 Randomized Clinical Trial.
    Castelli J; Thariat J; Benezery K; Hasbini A; Gery B; Berger A; Liem X; Guihard S; Chapet S; Thureau S; Auberdiac P; Pommier P; Ruffier A; Perrier L; Devillers A; Campillo-Gimenez B; de Crevoisier R
    JAMA Oncol; 2023 Aug; 9(8):1056-1064. PubMed ID: 37261806
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Parotid Gland Stem Cell Sparing Radiation Therapy for Patients With Head and Neck Cancer: A Double-Blind Randomized Controlled Trial.
    Steenbakkers RJHM; van Rijn-Dekker MI; Stokman MA; Kierkels RGJ; van der Schaaf A; van den Hoek JGM; Bijl HP; Kramer MCA; Coppes RP; Langendijk JA; van Luijk P
    Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):306-316. PubMed ID: 34563635
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Mesenchymal Stem/Stromal Cell Therapy for Radiation-Induced Xerostomia in Previous Head and Neck Cancer Patients: A Phase II Randomized, Placebo-Controlled Trial.
    Jakobsen KK; Carlander AF; Todsen T; Melchiors J; Paaske N; Østergaard Madsen AK; Kloch Bendtsen S; Mordhorst C; Stampe H; Kastrup J; Ekblond A; Haack-Sørensen M; Farhadi M; Maare C; Friborg J; Lynggaard CD; Werner Hauge A; Christensen R; Grønhøj C; von Buchwald C
    Clin Cancer Res; 2024 May; 30(10):2078-2084. PubMed ID: 38441659
    [TBL] [Abstract][Full Text] [Related]  

  • 106. A phase II study of submandibular gland transfer prior to radiation for prevention of radiation-induced xerostomia in head-and-neck cancer (RTOG 0244).
    Jha N; Harris J; Seikaly H; Jacobs JR; McEwan AJ; Robbins KT; Grecula J; Sharma AK; Ang KK
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):437-42. PubMed ID: 22541957
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Radioprotection of head and neck tissue by amifostine.
    Strnad V; Sauer R
    Front Radiat Ther Oncol; 2002; 37():101-11. PubMed ID: 11764651
    [No Abstract]   [Full Text] [Related]  

  • 108. [Cepharanthin effect on radiation-induced xerostomia and taste disorder in patients with head and neck cancer].
    Shimazu R; Tanaka G; Tomiyama R; Kuratomi Y; Inokuchi A
    Nihon Jibiinkoka Gakkai Kaiho; 2009 Sep; 112(9):648-55. PubMed ID: 19860267
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Systematic review and meta-analyses of intensity-modulated radiation therapy versus conventional two-dimensional and/or or three-dimensional radiotherapy in curative-intent management of head and neck squamous cell carcinoma.
    Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
    PLoS One; 2018; 13(7):e0200137. PubMed ID: 29979726
    [TBL] [Abstract][Full Text] [Related]  

  • 110. 3D-printed individualized tooth-borne tissue retraction devices compared to conventional dental splints for head and neck cancer radiotherapy: a randomized controlled trial.
    Held T; Herpel C; Schwindling FS; Christ L; Lang K; Regnery S; Eichkorn T; Hommertgen A; Jaekel C; Krisam J; Moratin J; Mrosek J; Metzger K; Zaoui K; Moutsis T; Harrabi S; Herfarth K; Freudlsperger C; Rammelsberg P; Debus J; Adeberg S
    Radiat Oncol; 2021 Apr; 16(1):75. PubMed ID: 33865401
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers.
    Gujral MS; Patnaik PM; Kaul R; Parikh HK; Conradt C; Tamhankar CP; Daftary GV
    Cancer Chemother Pharmacol; 2001 Jul; 47 Suppl():S23-8. PubMed ID: 11561868
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Safety and Efficacy of Mesenchymal Stem Cells for Radiation-Induced Xerostomia: A Randomized, Placebo-Controlled Phase 1/2 Trial (MESRIX).
    Grønhøj C; Jensen DH; Vester-Glowinski P; Jensen SB; Bardow A; Oliveri RS; Fog LM; Specht L; Thomsen C; Darkner S; Jensen M; Müller V; Kiss K; Agander T; Andersen E; Fischer-Nielsen A; von Buchwald C
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):581-592. PubMed ID: 29678523
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Pharmacologic normal tissue protection in clinical radiation oncology: focus on amifostine.
    Mell LK; Movsas B
    Expert Opin Drug Metab Toxicol; 2008 Oct; 4(10):1341-50. PubMed ID: 18798703
    [TBL] [Abstract][Full Text] [Related]  

  • 114. How to reduce radiation-related toxicity in patients with cancer of the head and neck.
    Garden AS; Lewin JS; Chambers MS
    Curr Oncol Rep; 2006 Mar; 8(2):140-5. PubMed ID: 16507224
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Alteration of radiation-induced hematotoxicity by amifostine.
    Momm F; Bechtold C; Rudat V; Strnad V; Tsekos A; Fischer K; Henke M
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):947-51. PubMed ID: 11704315
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Double-blind, placebo-controlled, randomized trial of granulocyte-colony stimulating factor during postoperative radiotherapy for squamous head and neck cancer.
    Su YB; Vickers AJ; Zelefsky MJ; Kraus DH; Shaha AR; Shah JP; Serio AM; Harrison LB; Bosl GJ; Pfister DG
    Cancer J; 2006; 12(3):182-8. PubMed ID: 16803675
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Toxicity profile of intensity-modulated radiation therapy for head and neck carcinoma and potential role of amifostine.
    Chao KS; Ozyigit G; Thorsdad WL
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):101-8. PubMed ID: 14727250
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Amifostine-induced fever: case report and review of the literature.
    Boehme S; Wilson DB
    Pharmacotherapy; 2004 Jan; 24(1):155-8. PubMed ID: 14740795
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Phase III quality-of-life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer--RTOG 97-09.
    Fisher J; Scott C; Scarantino CW; Leveque FG; White RL; Rotman M; Hodson DI; Meredith RF; Foote R; Bachman DG; Lee N
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):832-6. PubMed ID: 12788192
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Does amifostine have a role in chemoradiation treatment?
    Brizel DM; Overgaard J
    Lancet Oncol; 2003 Jun; 4(6):378-81. PubMed ID: 12788413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.